BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 24183837)

  • 1. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease.
    Kim H; Koh J; Park SK; Oh KH; Kim YH; Kim Y; Ahn C; Oh YK
    Nephrology (Carlton); 2019 Apr; 24(4):422-429. PubMed ID: 29797773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
    Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
    Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived Health and Quality of Life in Patients With CKD, Including Those With Kidney Failure: Findings From National Surveys in France.
    Legrand K; Speyer E; Stengel B; Frimat L; Ngueyon Sime W; Massy ZA; Fouque D; Laville M; Combe C; Jacquelinet C; Durand AC; Edet S; Gentile S; Briançon S; Ayav C
    Am J Kidney Dis; 2020 Jun; 75(6):868-878. PubMed ID: 31879215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
    Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
    Chen H; Watnick T; Hong SN; Daly B; Li Y; Seliger SL
    BMC Nephrol; 2019 Oct; 20(1):386. PubMed ID: 31653199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine Biomarkers and Perioperative Acute Kidney Injury: The Impact of Preoperative Estimated GFR.
    Koyner JL; Coca SG; Thiessen-Philbrook H; Patel UD; Shlipak MG; Garg AX; Parikh CR; ;
    Am J Kidney Dis; 2015 Dec; 66(6):1006-14. PubMed ID: 26386737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the Kidney Failure Risk Equation and Estimated GFR for Estimating Time to Kidney Failure in Advanced CKD.
    Chu CD; McCulloch CE; Hsu RK; Powe NR; Bieber B; Robinson BM; Raina R; Pecoits-Filho R; Tuot DS
    Am J Kidney Dis; 2023 Oct; 82(4):386-394.e1. PubMed ID: 37301501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Associations of Plant Protein Intake With All-Cause Mortality in CKD.
    Chen X; Wei G; Jalili T; Metos J; Giri A; Cho ME; Boucher R; Greene T; Beddhu S
    Am J Kidney Dis; 2016 Mar; 67(3):423-30. PubMed ID: 26687923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.